- Home
- SGHT vs SIFY Comparison
SGHT vs SIFY Comparison
Compare SGHT & SIFY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGHT
- SIFY
- Stock Information
- Founded
- SGHT 2011
- SIFY 1995
- Country
- SGHT United States
- SIFY India
- Employees
- SGHT N/A
- SIFY N/A
- Industry
- SGHT Medical Specialities
- SIFY Computer Software: Programming Data Processing
- Sector
- SGHT Health Care
- SIFY Technology
- Exchange
- SGHT Nasdaq
- SIFY Nasdaq
- Market Cap
- SGHT 304.4M
- SIFY N/A
- IPO Year
- SGHT 2021
- SIFY 1999
- Fundamental
- Price
- SGHT $3.68
- SIFY $3.50
- Analyst Decision
- SGHT Buy
- SIFY
- Analyst Count
- SGHT 6
- SIFY 0
- Target Price
- SGHT $6.80
- SIFY N/A
- AVG Volume (30 Days)
- SGHT 241.4K
- SIFY 90.3K
- Earning Date
- SGHT 11-07-2024
- SIFY 01-16-2025
- Dividend Yield
- SGHT N/A
- SIFY N/A
- EPS Growth
- SGHT N/A
- SIFY N/A
- EPS
- SGHT N/A
- SIFY N/A
- Revenue
- SGHT $79,543,000.00
- SIFY $443,027,157.00
- Revenue This Year
- SGHT $2.18
- SIFY N/A
- Revenue Next Year
- SGHT $8.14
- SIFY $12.52
- P/E Ratio
- SGHT N/A
- SIFY $63.84
- Revenue Growth
- SGHT N/A
- SIFY 5.85
- 52 Week Low
- SGHT $2.58
- SIFY $1.80
- 52 Week High
- SGHT $8.45
- SIFY $12.30
- Technical
- Relative Strength Index (RSI)
- SGHT 32.94
- SIFY 59.46
- Support Level
- SGHT $3.86
- SIFY $3.25
- Resistance Level
- SGHT $4.11
- SIFY $3.69
- Average True Range (ATR)
- SGHT 0.18
- SIFY 0.19
- MACD
- SGHT 0.05
- SIFY 0.03
- Stochastic Oscillator
- SGHT 3.75
- SIFY 82.08
About SGHT Sight Sciences Inc.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.